WuXi AppTec delivered robust financial performance in the first half of 2026, reporting a 38.9% year-on-year increase in total revenue to RMB 28.90 billion. The Shanghai-based Contract Research, Development, and Manufacturing Organization (CRDMO) raised its full-year guidance across revenue, capital expenditure, and free cash flow metrics, citing strong execution and the greater success of multiple customers' products. This growth trajectory underscores the effectiveness of its integrated platform in capturing market share within the global pharmaceutical services sector.

Adjusted non-IFRS net profit climbed significantly by 83.2% year-on-year to RMB 11.57 billion, with the margin expanding 9.7 percentage points to 40.0%. Under China Accounting Standards (CAS), net profit rose 29.4% to RMB 11.08 billion. The company’s backlog for continuing operations grew 25.2% to RMB 66.43 billion as of June 30, 2026, providing visibility into future earnings. Adjusted operating cash flow also strengthened, rising 41.3% to RMB 9.98 billion.

Financial Performance Highlights

Dr. Ge Li, Chairman and CEO of WuXi AppTec, attributed the results to the company's unique CRDMO model and global team perseverance. He noted that achievements are rooted in the exceptional performance of their customers. Management emphasized that the strong H1 performance justifies the upward revision of all 2026 guidance metrics and has accelerated plans for global capacity expansion, including the early initiation of the new Changzhou site.

Revised Full-Year Outlook

The company raised its 2026 total revenue target to RMB 58.5-60.5 billion, up from the previous guidance of RMB 51.3-53.0 billion. Revenue from continuing operations is now expected to grow 35-39% year-on-year, compared to the prior estimate of 18-22%. Capital expenditure guidance was increased to RMB 7.5-8.5 billion from RMB 6.5-7.5 billion to support these expansions. Consequently, adjusted free cash flow for 2026 was raised to RMB 13.5-14.5 billion, up from RMB 10.5-11.5 billion.

Shareholder Returns and Governance

WuXi AppTec distributed a 2025 annual cash dividend totaling RMB 4.71 billion. The Board has proposed an increase in the 2026 interim cash dividend to RMB 5.10 per 10 shares, amounting to approximately RMB 1.5 billion in total. In terms of governance and compliance, the company maintained its "AAA" MSCI ESG rating and completed 465 quality audits and inspections with no critical findings. Twenty main sites are now ISO/IEC 27001 certified.

What the Numbers Show

The divergence between the 38.9% growth in total revenue and the 83.2% surge in adjusted non-IFRS net profit indicates significant operating leverage. The expansion of the adjusted non-IFRS gross profit margin by 9.4 percentage points to 53.9% suggests that higher-margin activities, likely driven by the successful commercialization of customer products, are contributing disproportionately to the bottom line. This margin expansion, combined with a 25.2% rise in backlog, points to a sustainable improvement in profitability rather than one-off gains.

The company also addressed recent geopolitical challenges, noting that the U.S. Department of Defense included WuXi AppTec on its 1260H list. Dr. Ge Li described this designation as erroneous and unsupported by facts or law, stating that legal action has been taken to protect the interests of customers, employees, and shareholders.

WuXi AppTec, a leading global pharmaceutical Contract Research, Development, and Manufacturing Organization (CRDMO), has been named a constituent of the FTSE4Good Index Series for the fourth consecutive year. This inclusion reflects the company's sustained commitment to sustainability and strong environmental, social, and governance (ESG) practices. The recognition serves as a benchmark for investors seeking to align their portfolios with positive corporate behavior.

The FTSE4Good Index Series, created by FTSE Russell, assesses the performance of companies demonstrating robust sustainability practices. In the most recent assessment cycle, WuXi AppTec achieved the highest score of 5 points in Corporate Governance, Anti-Corruption, and Labor Standards. Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of the company's Sustainability Committee, stated that the acknowledgement affirms the capital markets' confidence in WuXi AppTec's sustainable management practices.

WuXi AppTec integrates sustainability throughout its operations to align with the values of its customers and partners. The company's sustainability performance has received notable recognition from leading global rating agencies. These include an "AAA" rating in MSCI, an "A List" designation from CDP for Climate Change, Water Security, and Supplier Engagement, and a "Gold" medal in the EcoVadis Sustainability Rating. Additionally, the company has been selected for the Dow Jones Best-in-Class World Index and the S&P Global Sustainability Yearbook, and received the "Prime" award in the ISS ESG Corporate Rating.

Furthering its commitments, WuXi AppTec's near-term greenhouse gas emissions reduction targets have been validated by the Science Based Targets initiative (SBTi). The company is a participant in the United Nations Global Compact (UNGC) and supports its ten principles. It also serves as a supplier partner to the Pharmaceutical Supply Chain Initiative (PSCI).

Sustainability Ratings and Recognitions

WuXi AppTec holds multiple sustainability certifications and ratings from global organizations:

WuXi AppTec provides R&D and manufacturing services to advance healthcare innovation, with operations across Asia, Europe, and North America.